Rociletinib

From WikiMD.org
Jump to navigation Jump to search

Rociletinib (pronounced roh-si-let-in-ib) is a pharmaceutical drug used in the treatment of non-small cell lung cancer (NSCLC). It is a third-generation epidermal growth factor receptor (EGFR) inhibitor, specifically designed to target mutant forms of the EGFR gene that have become resistant to first and second-generation EGFR inhibitors.

Etymology

The name "Rociletinib" is derived from the pharmaceutical company Clovis Oncology that developed the drug. The "rocil" part of the name is a tribute to the company, while "tinib" is a common suffix for tyrosine kinase inhibitors, which is the class of drugs to which Rociletinib belongs.

Usage

Rociletinib is used for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after EGFR TKI therapy. It is administered orally.

Mechanism of Action

Rociletinib inhibits the activity of the EGFR tyrosine kinase, which is a protein involved in the growth and spread of cancer cells. By inhibiting this protein, Rociletinib can slow down or stop the growth of NSCLC cells.

Side Effects

Common side effects of Rociletinib include diarrhea, nausea, vomiting, and fatigue. More serious side effects can include liver problems, heart problems, and eye problems.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski